Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Validea
$12.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC Reaffirms FY 2013 Guidance


Thursday, 31 Oct 2013 03:00am EDT 

AstraZeneca PLC announced that for fiscal 2013, it continues to anticipate a mid-to-high single-digit decline in revenue on a constant currency basis and Core EPS to decline at a rate that is significantly higher than the decline in revenue in fiscal 2013. The Company reported revenue of $27.973 billion and EPS of $6.41 in fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $26.009 billion and EPS of $5.13 for fiscal 2013. 

Company Quote

4743.0
-18.5 -0.39%
30 Jan 2015